95 related articles for article (PubMed ID: 14739666)
21. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Zustovich F; Lombardi G; Della Puppa A; Rotilio A; Scienza R; Pastorelli D
Anticancer Res; 2009 Oct; 29(10):4275-9. PubMed ID: 19846986
[TBL] [Abstract][Full Text] [Related]
22. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS
J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
[TBL] [Abstract][Full Text] [Related]
24. 5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group.
Roth BJ; Elson P; Sledge GW; Einhorn LH; Trump DL
Invest New Drugs; 1993; 11(2-3):201-2. PubMed ID: 7505269
[No Abstract] [Full Text] [Related]
25. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
26. Salvage resection of a chemorefractory mediastinal germ cell tumor.
Rivoire M; Voiglio E; Kaemmerlen P; Treilleux I; Biron P; Droz JP
J Thorac Cardiovasc Surg; 1996 Oct; 112(4):1124-6. PubMed ID: 8873747
[No Abstract] [Full Text] [Related]
27. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
28. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Rick O; Siegert W; Beyer J
Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
[TBL] [Abstract][Full Text] [Related]
30. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of everolimus in refractory testicular germ cell tumors.
Mego M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rajec J; Sycova-Mila Z; Chovanec M; Rejlekova K; Zuzák P; Ondrus D; Spanik S; Reckova M; Mardiak J
Urol Oncol; 2016 Mar; 34(3):122.e17-22. PubMed ID: 26612480
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience.
Gerl A; Clemm C; Lamerz R; Wilmanns W
Cancer; 1996 Feb; 77(3):526-32. PubMed ID: 8630961
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
[TBL] [Abstract][Full Text] [Related]
34. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
35. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Bajorin DF; Bosl GJ; Lyn P; Vlamis V
J Clin Oncol; 1997 Jul; 15(7):2546-52. PubMed ID: 9215823
[TBL] [Abstract][Full Text] [Related]
36. High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer.
Sleijfer S; Van der Graaf WT; Willemse PH; De Vries EG; Schraffordt Koops H; Mulder NH
Anticancer Res; 1995; 15(3):1039-42. PubMed ID: 7544087
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
Feldman DR; Kondagunta GV; Ginsberg MS; Ishill N; Patil S; Cestaro J; Obbens E; Sheinfeld J; Bosl GJ; Motzer RJ
Invest New Drugs; 2007 Oct; 25(5):487-90. PubMed ID: 17520176
[TBL] [Abstract][Full Text] [Related]
38. Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation.
Adkins D; Encarnacion C; Salzman D; Boldt D; Freytes C; Von Hoff DD; LeMaistre CF
Bone Marrow Transplant; 1993 Nov; 12(5):541-6. PubMed ID: 7507767
[TBL] [Abstract][Full Text] [Related]
39. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
40. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.
Spierings DC; de Vries EG; Vellenga E; de Jong S
Cell Death Differ; 2003 Jul; 10(7):808-22. PubMed ID: 12815464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]